By David Bautz, PhD NASDAQ:ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in ...

Caribou Biosciences announces new clinical trials and leadership appointments, highlighting progress in CAR-T therapy for various cancers and lupus. Caribou Biosciences, Inc. announced the initiation ...

DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...

CEO Carl Hansen highlighted the company's progress in its transition to a clinical-stage biotech with the advancement of its two lead programs, ABCL635 and ABCL575. ABCL635, a potential first-in-class ...

Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...

Impact of SARS-CoV-2 mRNA-BNT162b2 vaccination on survival outcomes in metastatic colorectal cancer patients treated with bevacizumab-based therapy. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data ...

January 16, 2007 — Because phase 1 oncology trials are typically carried out in patients who are in advanced stages of disease and investigate untried therapies, they offer a relatively low prospect ...